Table 3.
Summary ORs of p53 and GSTP1 polymorphisms and esophageal cancer risk
| Comparison | No. of Cases | No. of Controls | OR | 95%CI | P* |
|---|---|---|---|---|---|
| p53 Arg75Pro | |||||
| Pro/Arg vs Arg/Arg | 1761 | 2850 | 1.09 | 0.95-1.24 | 0.25 |
| Pro/Pro vs Arg/Arg | 1720 | 2263 | 1.43 | 1.23-1.68 | 0.06 |
| Pro/Pro vs (Arg/Arg+Pro/Arg) | 2919 | 4074 | 1.31 | 0.95-1.80 | 0.00 |
| (Pro/Arg +Pro/Pro) vs Arg/Arg | 2919 | 4074 | 1.20 | 1.06-1.36 | 0.08 |
| GSTP1 Ile106Val | |||||
| Ile/Val vs Ile/Ile | 1687 | 1917 | 0.99 | 0.74-1.32 | 0.00 |
| Val/Val vs Ile/Ile | 1063 | 1295 | 1.00 | 0,81-1.23 | 0.28 |
| Val/Val vs (Ile/Ile+Ile/Val) | 1885 | 2194 | 0.95 | 0.79-1.17 | 0.57 |
| (Ile/Val+Val/Val) vs Ile/Ile | 1885 | 2194 | 0.95 | 0.73-1.25 | 0.00 |
* Test for heterogeneity. Fixed-effects model was used when P value for heterogeneity test > 0.05; otherwise, random-effects model was used.